ARK Investment Management LLC Cuts Stock Holdings in Repare Therapeutics Inc. (NASDAQ:RPTX)

ARK Investment Management LLC lowered its stake in Repare Therapeutics Inc. (NASDAQ:RPTX) by 20.3% during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 1,999,997 shares of the company’s stock after selling 509,740 shares during the period. ARK Investment Management LLC owned approximately 4.70% of Repare Therapeutics worth $2,620,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors also recently modified their holdings of the company. Barclays PLC raised its holdings in Repare Therapeutics by 1,471.7% during the 3rd quarter. Barclays PLC now owns 8,330 shares of the company’s stock valued at $29,000 after buying an additional 7,800 shares during the last quarter. Vontobel Holding Ltd. increased its position in shares of Repare Therapeutics by 45.8% in the fourth quarter. Vontobel Holding Ltd. now owns 35,000 shares of the company’s stock valued at $46,000 after acquiring an additional 11,000 shares during the period. Finally, Stifel Financial Corp increased its position in shares of Repare Therapeutics by 36.4% in the third quarter. Stifel Financial Corp now owns 51,700 shares of the company’s stock valued at $178,000 after acquiring an additional 13,800 shares during the period. Institutional investors own 85.09% of the company’s stock.

Repare Therapeutics Price Performance

RPTX stock opened at $1.25 on Thursday. Repare Therapeutics Inc. has a 1 year low of $1.10 and a 1 year high of $7.45. The firm has a 50-day moving average of $1.27 and a 200 day moving average of $2.51. The company has a market cap of $53.14 million, a P/E ratio of -0.63 and a beta of 0.88.

Analyst Ratings Changes

A number of analysts have recently weighed in on the stock. Lifesci Capital reiterated a “market perform” rating on shares of Repare Therapeutics in a report on Friday, December 13th. Stifel Nicolaus dropped their price objective on Repare Therapeutics from $9.00 to $4.00 and set a “buy” rating for the company in a report on Friday, December 13th. HC Wainwright reissued a “buy” rating and set a $10.00 target price on shares of Repare Therapeutics in a research note on Friday, November 8th. Finally, Bloom Burton downgraded Repare Therapeutics from a “strong-buy” rating to a “hold” rating in a report on Friday, January 10th.

About Repare Therapeutics

Repare Therapeutics Inc, a clinical-stage precision oncology company, engages in the discovery and development of therapeutics by using its synthetic lethality approach in Canada and the United States. It uses its SNIPRx, a proprietary, genome-wide, and CRISPR-enabled platform, to discover, validate, and build a pipeline of SL-based therapeutics that focuses on genomic instability, including DNA damage repair.